ABSTRACT: Transradial artery access for percutaneous coronary intervention is associated with lower bleeding and vascular complications than transfemoral artery access, especially in patients with acute coronary syndromes. A growing body of evidence supports adoption of transradial artery access to improve acute coronary syndrome-related outcomes, to improve healthcare quality, and to reduce cost. The purpose of this scientific statement is to propose and support a "radial-first" strategy in the United States for patients with acute coronary syndromes. This document also provides an update to previously published statements on transradial artery access technique and best practices, particularly as they relate to the management of patients with acute coronary syndromes. T ransradial artery access (TRA) for percutaneous coronary intervention (PCI) is associated with lower bleeding and vascular complications than transfemoral artery access (TFA), especially in patients with acute coronary syndromes (ACS).
T ransradial artery access (TRA) for percutaneous coronary intervention (PCI) is associated with lower bleeding and vascular complications than transfemoral artery access (TFA), especially in patients with acute coronary syndromes (ACS). [1] [2] [3] [4] [5] [6] [7] [8] [9] Use of TRA for coronary angiography and PCI may also be associated with improved measures of quality of life and reduced costs compared with TFA. 1, 2, [10] [11] [12] [13] [14] [15] Although the use of TRA is growing in the United States, its uptake has lagged behind some of the larger markets in Western Europe and Asia. 5, [16] [17] [18] [19] [20] [21] A growing body of evidence supports adoption of TRA to improve ACS-related outcomes, to improve healthcare quality, and to reduce cost. Much of this evidence has emerged since the most recent updates of the American Heart Association/American College of Cardiology Foundation joint practice guidelines for PCI and for the management of ST-segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation ACS. [22] [23] [24] [25] However, the 2015 European Society of Cardiology guidelines for the management of ACS recommended TRA as the preferred method of access (Class I indication). 26 The purpose of this scientific statement is to propose and support a "radial-first" strategy in the United States for patients with ACS. [22] [23] [24] [25] This document also provides an update to previously published statements on TRA technique and best practices, particularly as they relate to the management of patients with ACS. 27, 28 
EVIDENCE-BASED REVIEW OF TRA IN ACS Methods
A literature search of outcomes after PCI with TRA or TFA was performed with the PubMed database through June 2017 to supplement the recent meta-anal-yses that have been performed on this subject. 1, 2 We included in our analysis all published reports that were cited in the previous meta-analyses and any additional studies that were independently identified. Main trial results are summarized in the Table and the Data  Supplement. 1,2,5,6,10, Major end points for this systematic review were major bleeding, vascular complications, and mortality. Two authors independently abstracted data from 19 randomized clinical trials (RCTs) that contained information about these end points in a total of 21 134 patients. 1, 2, 5, 6, 10, All of the RCTs reported major bleeding, but the definition of vascular complications varied from trial to trial. All-cause mortality was reported in all but 1 RCT, which reported cardiovascular mortality only. 6 Standard meta-analyses were performed for the major end points with the open-source statistical program R 3.0.3 and library package meta 3.8-0. [59] [60] [61] Analyses were stratified by the presence or absence of ACS. Absolute differences and numbers needed to treat were calculated from weighted rates for each end point from the random-effects model. 61 
Bleeding Complications
Bleeding complications occurred in ≈1.2% to 16% of all patients. Although the definition of bleeding, the underlying patient risk, and the use of concomitant antithrombotic therapies varied across studies, both major and minor bleeding events were associated with a higher risk of short-and long-term mortality. 1, 6, 7, 62 Access site-related bleeding accounted for slightly less than one-half of bleeding events in patients undergoing PCI. Although access site bleeding had a better prognosis than non-access site bleeding, both were associated with increased mortality. 7 Observational studies reported a lower rate of both minor and major bleeding complications associated with TRA compared with TFA, 3, 4, [63] [64] [65] [66] [67] [68] [69] whereas RCTs demonstrated a reduction in bleeding events with TRA that was driven largely by lower rates of minor bleeds. 32, 35, 40, 53 In the international, multicenter RIVAL trial (Radial Versus Femoral Access for Coronary Intervention), no significant difference was noted between TRA and TFA for protocol-defined major bleeds. 1 However, the trial had a very low overall major bleeding rate (<0.5%) and a lower rate of access site-related bleeding. A post hoc analysis performed according to the access site used for procedure completion demonstrated that major bleeds were lower with TRA (0.6% versus 1.0%; hazard ratio [HR] , 0.53; 95% confidence interval [CI] , 0. 30-0.92) . This finding, however, is confounded by the higher bleeding rate observed in patients who crossed over from TRA to TFA. Analysis of bleeding end points with the more inclusive ACUITY trial (Acute Catheterization and Urgent Intervention Triage Strategy) bleeding definition found a greater relative reduction in bleeding associated with TRA than with TFA (1.9% versus 4.5%; P<0.0001). Consistent with these findings, the MATRIX trial (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX) demonstrated that patients with ACS randomized to TRA had a significantly lower rate of the coprimary end point of net adverse events, defined as a composite of death, myocardial infarction, stroke, or major bleeding event. 2 This was driven predominantly by a lower rate of noncoronary artery bypass graft (CABG)-related major bleeding in the TRA group (1.6% versus 2.3%; relative risk, 0.67; 95% CI, 0.49-0.92).
Even larger reductions in bleeding and vascular complications are noted with TRA in patients with STEMI. In the RIFLE-STEACS trial (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome), protocol-defined major bleeding occurred in 7.8% of patients with TRA and 12.2% with TFA (P=0.026). 5 The study enrolled higher-risk patients, including those who failed fibrinolysis and those with cardiogenic shock or hemodynamic instability, which likely contributed to higher overall rates of bleeding. TRA was associated with a 60% lower rate of access site bleeding than TFA (2.6% versus 6.8%; P=0.002), whereas no significant difference was noted between the groups for non-access site bleeding. In the STEMI-RADIAL trial (ST Elevation Myocardial Infarction Treated by Radial or Femoral Approach), the primary composite end point of major bleeding and vascular complications occurred in 1.4% of patients with TRA and 7.2% with TFA (P=0.0001). 6 This was driven by a lower rate of very large hematomas in the TRA group. In a prespecified subgroup analysis of patients with STEMI in the RIVAL trial, the rates of non-CABG major (0.84% versus 0.91%) and access site (0.1% versus 0.2%) bleeding events were not different between TRA and TFA. However, ACUITY major bleeding occurred in 1.9% of patients with TRA and 4.1% of patients with TFA (P=0.009), a difference that was driven by access site-related bleeding events (1.2% versus 3.39%; P=0.003). 9 As Figure 1 shows, major bleeding was lower after TRA PCI compared with TFA PCI in trials that enrolled patients with either stable ischemic heart disease or ACS (odds ratio [OR], 0.21; 95% CI, 0.08-0.52) and in trials that enrolled ACS patients only (OR, 0.60; 95% CI, 0.47-0.76). In patients with ACS undergoing TRA PCI, the weighted bleeding rate was 3.4% (95% CI, 2.7-4.3), which was lower than the weighted bleeding rate of 5.5% in the TFA group (P<0.05). For every 1000 patients with ACS undergoing TRA PCI, there were 21 fewer bleeding events (95% CI, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , and the corresponding number needed to treat with TRA to prevent 1 major bleeding event was 47 (95% CI, 35-79). These studies did not report radial artery (RA) occlusion (RAO) as a vascular complication, likely because the clinical significance of RAO remains controversial. In the RIVAL trial, the incidence of major vascular access site complications was significantly lower in the TRA group (1.4% versus 3.7%; HR, 0.37; 95% CI, 0.27-0.52), and the incidence of symptomatic RAO was extremely low (0.2%). 1 In patients with STEMI, the incidence of major vascular access complications was 1.2% with TRA and 3.4% with TFA (P=0.002). 9 Although the overall incidence of major vascular complications in the MATRIX trial was low, patients randomized to TRA had a lower likelihood of complications that required surgical repair (0.1% versus 0.4%; relative risk, 0.27; 95% CI, 0.09-0.80). 2 In the STEMI-RADIAL trial, vascular complications were uncommon and not significantly different between TRA and TFA (0.3% versus 0.8%; P=0.62). 6 As Figure 2 shows, vascular complications (excluding RAO) were lower after TRA PCI compared with TFA PCI (OR, 0.35; 95% CI, 0.24-0.50). In patients undergoing TRA PCI, the weighted major vascular complication rate was 2.9% (95% CI, 2.0-4.0), which was lower than the weighted vascular complication of 7.7% in the TFA group (P<0.05). For every 1000 patients with ACS undergoing TRA PCI, there were 48 fewer vascular complications (95% CI, , and the corresponding number needed to treat with TRA to prevent 1 vascular complication was 21 (95% CI, 18-27).
Mortality
Although there were no differences in major adverse cardiovascular events in the RIVAL trial, a prespecified subanalysis demonstrated a significant interaction of the effect of arterial access on the primary composite outcome of death, myocardial infarction, stroke, and non-CABG major bleeding as a function of the type of presenting syndrome (P for interaction=0.025), 9 with patients with STEMI deriving the most benefit from TRA. In addition, in patients with STEMI, all-cause mortality at 30 days was significantly lower with TRA compared with TFA (HR, 0.39; 95% CI, 0.20-0.76; P for interaction=0.001). In the MATRIX trial, TRA was associated with a reduction in death at 30 days compared with TFA in patients with ACS (1.6% versus 2.2%; relative risk, 0.72; 95% CI, 0.53-0.99). 2 In the RIFLE-STEACS trial, TRA also resulted in lower cardiac mortality than TFA did (5.2% versus 9.2%; P=0.02). 5 The RIVAL, MATRIX, and RIFLE-STEACS trials included a heterogeneous group of patients with STEMI, some of whom underwent rescue PCI or PCI after fibrinolytic therapy. The STEMI-RADIAL study, however, enrolled only patients with STEMI undergoing primary PCI and demonstrated no differences in mortality between the TRA and TFA groups (2.3% versus 3.1%; P=0.64). 6 As Figure 3 shows, all-cause mortality was not different after TRA PCI compared with TFA PCI in trials that enrolled patients with either stable ischemic heart disease or ACS (OR, 1.43; 95% CI, 0. 58-3.50 
Access Site Crossover
Despite advances in devices and technique, access site crossover remains an important limitation of TRA. Realworld estimates of crossover rates have varied (4.6%-10%), but operator experience consistently predicts rates of crossover. [72] [73] [74] [75] The RIVAL trial showed that the rate of access site crossover was higher in TRA compared with TFA (7.6% versus 2%; HR, 3.82; 95% CI, 2.93-4.97) but that crossover was lower in centers with higher PCI volume (4.4% versus 2.3%; HR, 1.92; 95% CI, 1.19-3.08).
1 RCTs that included operators who performed between 50 and 75 TRA PCIs in the preceding year demonstrated TRA to TFA crossover rates of 3% to 7%. 1, 4, 5, 55 Some data suggest that the use of left (LRA) over right RA (RRA) might help reduce crossover rates because of the lower prevalence of left-sided brachiocephalic tortuosity. 76, 77 Finally, crossover rates are also reduced with ultrasound guidance.
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Radiation Exposure
Observational studies and randomized data have demonstrated longer fluoroscopy times with TRA procedures.
1,2,39,79-82 However, assessments of radiation exposure as measured by the more accurate parameter of dose-area product have reported mixed results. Some studies demonstrated a higher dosearea product with TRA, 46, 79 whereas others reported no difference, 57, 82 and 1 study reported a lower dosearea product with TRA. 80 Most recently, RAD-MATRIX (Radiation Substudy of MATRIX) demonstrated greater radiation exposure with TRA even in this setting of experienced TRA operators. 83 Use of left versus right TRA also demonstrated mixed findings for radiation exposure. 57, 79, 82, 83 However, studies demonstrate that summed radiation exposure to both the patient and the operator is reduced with the use of lower-dose fluoroscopy and, at centers with a higher annual TRA volume, lower radiation exposure to the operator with additional radiation protection drapes.
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Contrast Volume
Most studies have demonstrated no difference or lower contrast volume with TRA compared with TFA. 2, 5, 33, 35, 37, 39, 43, 45, 49, 86, 87 Contrast volume appeared to be lower in procedures performed by high-volume TRA operators. 88 In a retrospective propensity-matched comparison, TRA was associated with a lower rate of contrast-induced nephropathy (OR, 0.60; 95% CI, 0.40-0.92), whereas another observational study of patients with STEMI did not show a difference in this end point (OR, 0.65; 95% CI, 0.32-1.30). 87, 89 A recent report from the MATRIX trial demonstrated that acute kidney injury occurred in 15.4% of patients who were randomized to TRA and in 17.4% of patients randomized to TFA (OR, 0.87; 95% CI, 0.77-0.98). 90 Further investigation in this area is warranted. and to improve patient quality-of-life metrics compared with TFA. 1, 10, 11, 26, 91 A single-center RCT in patients with stable ischemic heart disease demonstrated that TRA is associated with less overall discomfort, body pain, and back pain, whereas scores related to the ability to walk and use the bathroom were all better compared with TFA. 10 A subset of patients in the randomized SAFE-PCI for Women trial (Study of Access Site for Enhancement of PCI for Women) were evaluated with the European Quality of Life-5 Dimensions instrument. 11 TRA was associated with more difficulty with self-care and routine activities that required the hand, whereas TFA was associated with slightly more difficulty walking. Despite the absence of demonstrable quality-of-life differences, when asked about their access preference for a hypothetical future procedure, 77% of patients with TRA preferred TRA, whereas 26.8% of patients with TFA preferred TFA (P<0.0001). Similar results were found among female participants in the RIVAL trial, in which 90.2% of patients with TRA expressed preference for the access site to which they were randomized in case of a second procedure compared with 50.7% of patients with TFA (P<0.0001). 92 Long-term arm and hand function is not altered at 1 year after TRA procedures and is a subject of an ongoing clinical trial. 93, 94 Although these findings are not validated in dedicated ACS trials, it is reasonable to expect that similar advantages in patient satisfaction and quality metrics would be observed with TRA in the ACS population, as has been demonstrated in patients with stable ischemic heart disease. 
Additional Benefits of TRA in ACS
Healthcare Costs
The impact of TRA and related patient care pathways on healthcare costs is an evolving topic and the focus of active investigation but is also limited in data specific to the management of patients with ACS. Current data suggest that cost savings related to TRA are derived primarily from lower vascular and bleeding complication rates, shorter average intensive care unit and hospital lengths of stay, and minor differences in procedure costs. A meta-analysis of 14 studies demonstrated that the benefits of TRA in terms of lower complication rates and shorter hemostasis time outweighed the potentially longer procedural time and higher crossover rates and resulted in an estimated direct cost saving of $275 per patient. 12 A subsequent retrospective analysis of a large national administrative hospital database showed that the use of TRA in PCI decreased overall costs by $533 (95% CI, 445-1010; P=0.033). 13 Although "day of" costs between TRA and TFA PCI were not different, costs from the procedure to hospital discharge were significantly lower for patients undergoing TRA. Furthermore, there was a graded increase in cost savings according to bleeding risk, with a $1621 cost savings with TRA (95% CI, 271-2971; P=0.039) in patients at high predicted bleeding risk such as those with ACS. In a small RCT of patients undergoing PCI for ACS, TRA was associated with a decrease by 1.5 days in hospital stay and a decrease from $23 389 to $20 476 in hospital charges. 14 In the RIFLE-STEACS trial, time spent in the intensive care unit and overall hospital length of stay were significantly lower in patients randomized to TRA compared with those randomized to TFA. 5 Similarly, a small RCT in patients with STEMI in Poland demonstrated that compared with TFA the TRA approach was associated with shorter length of stay, lower cost of therapeutic success, and lower indirect patient costs. 95 Finally, a recent analysis of patients undergoing PCI for stable and unstable coronary artery disease in the National Cardiovascular Data Registry demonstrated an adjusted cost difference of $916 (95% CI, 778-1035) in 2014 US dollars with TRA compared with TFA. 4 
RECOMMENDATIONS AND BEST PRACTICES FOR TRA IN ACS Operator Proficiency
Although the relative benefits of TRA over TFA are most pronounced in high-risk patient subgroups such as those with ACS, maintenance of adequate operator and center volume is important in realizing these benefits. Analyses of the TRA learning curve suggest that operator proficiency may reduce concerns about access site crossover, radiation exposure, contrast volume, delay in reperfusion time, and procedural success. 74, [96] [97] [98] Although requisite procedure volumes to achieve (>50 cases) and maintain (>80 procedures a year) proficiency have been proposed, many factors determine operator and center expertise in the TRA technique. 26, 27 Furthermore, the relationship between volume and procedural success does not appear to have a threshold. 99 Predictors of PCI failure with TRA catheterization include increasing age (≥75 years), female sex, previous CABG, cardiogenic shock, and short stature. 77, 100 It is recommended that operators and centers pursue a radial-first strategy and a graduated exposure to case complexity with a transition plan for the ACS setting. Plans to pursue TRA in STEMI and cardiogenic shock may need to be deferred until both the center and the operator have sufficient experience to ensure operator and staff comfort in achieving acceptable procedural times.
TRA Technique
Patient Selection
Assuming appropriate operator and center experience, a radial-first approach to an all-comers population is strongly encouraged. The relative benefits of TRA may be especially pronounced in patients on therapeutic oral anticoagulation, at risk of bleeding because of medical comorbidities (eg, at extremes of body mass index, chronic kidney disease, thrombocytopenia), or unable to receive blood transfusion. 46, 101 TRA is also preferable in patients who have difficulty lying flat (eg, those with congestive heart failure, low back pain, cognitive impairment).
Relative contraindications to the radial approach are limited but include severe vaso-occlusive disease (eg, Raynaud disease, Takayasu arteritis, thromboangiitis obliterans), documented small RA size, or known complex radial or brachiocephalic anatomy. The impact of TRA on subsequent utility of the RA as a bypass conduit or in patients who may subsequently require arteriovenous fistula creation remains an area of uncertainty.
Although a radial-first approach is strongly recommended, appropriate TFA procedure volume and adherence to best practices in femoral access are important in maintaining the skills and experience necessary when TRA is not an option. Accordingly, some operators may choose to pursue TFA in low-risk elective patients or in select patient subgroups in whom TRA is anticipated to be difficult or is associated with some uncertainty. Alternatively, operator TFA volume can be maintained through peripheral vascular, structural heart, or ventricular assist device insertion procedures.
Preprocedural Assessment
Although assessment of the RA pulse is important, performing an Allen or Barbeau test to confirm the patency of dual arterial circulation to the hand and intact palmar arch system is only of historical interest. Recent reports of patients with normal and abnormal preprocedural Allen test who subsequently underwent TRA did not demonstrate differences in thumb capillary lactate, grip strength, or incidence of ischemia between the 2 groups. 102, 103 Routine application of the Allen or Barbeau test is not a useful triage strategy, and an abnormal test should not preclude TRA. However, use of ultrasound imaging or the reverse Allen or Barbeau test may be helpful in identifying an occluded RA that fills via retrograde collaterals. In addition, the use of ultrasound imaging that is inclusive of the antecubital fossa may help reduce crossover rates through the identification of radial loops and other vascular anomalies.
Access Site Selection and Patient Setup
Although the RRA is often preferred for reasons of operator comfort and limitations of typical catheterization laboratory radiation safety equipment design, 104 the LRA is considered in certain situations such as in patients with a left internal mammary bypass or those of short stature and >75 years of age. 76, 77 Finally, some operators transitioning from TFA to TRA may prefer the familiarity of catheter fit and engagement between TFA and LRA.
Safe and successful PCI in the ACS setting requires appropriate patient setup. For RRA procedures, a platform that provides transitional support between the access site and procedure table for wires and catheters is recommended. Operator comfort can be improved in LRA procedures by elevating the patient's arm (eg, with sheets, pillow, or foam board) and retracting it across the patient's body. Alternative approaches described include access of the LRA through the dorsal aspect of the thumb in the anatomic snuffbox, 105 but long-term safety implications of this technique and its application to the ACS setting are uncertain.
Ulnar artery access is a potential alternative to radial access. Compared with the RA, the ulnar artery is in a less favorable and deeper anatomic position that is associated with a less readily palpable pulse and more challenging hemostatic control. Unlike the RA, the ulnar artery is also immediately adjacent to a large nerve. These issues noted, the data indicate that, in experienced hands, transulnar access is noninferior in safety and efficacy to TRA. [106] [107] [108] [109] Adjunctive use of ultrasound to guide arterial access is recommended to help minimize hematomas and patient discomfort.
108-111
Access Technique
In patients with ACS, especially those with STEMI, efficient and safe acquisition of arterial access is critical. TRA is facilitated with the palm securely positioned supinated, gently hyperextended at the wrist, and parallel to the floor. Arterial access may be obtained via either single-or double-wall puncture technique. Both techniques are safe and effective and are associated with low rates of RAO and other complications. However, the double-wall technique is associated with a higher first-pass success rate. 112 In addition, ultrasound guidance may be beneficial, particularly in patients with a weak pulse, hypotension, or cardiogenic shock or for ulnar access. The randomized RAUST trial (Radial Artery Access With Ultrasound Trial) demonstrated reduced time and number of attempts to achieve arterial access with ultrasound guidance. 79 In patients with cardiogenic shock, ultrasound guidance and the administration of vasopressor therapy (eg, norepinephrine, 100-µg bolus) also facilitate TRA use. 78, 111, 112 Dedicated radial sheaths that feature a tapered dilator and hydrophilic-coating engender less RA spasm and improve patient comfort. 113, 114 To reduce rates of RAO, it is advisable to use the smallest-caliber sheath possible. However, the "slender" approach (both sheath and catheter) to reduce rates of RAO and to facilitate hemostasis and recovery needs to be validated in larger trials. Finally, sheath length has not been demonstrated to affect patient comfort, RA spasm, RAO, or procedural safety. 114 Operators may consider securing the hydrophilic sheath in place with a transparent semipermeable dressing.
Summary of Recommendations
• A radial-first approach is strongly recommended in all patients, but a graduated level of center and operator experience is recommended before TRA is pursued in patients with ACS.
• Noninvasive testing for collateral hand circulation (Allen or Barbeau test) does not predict adverse outcomes and should not be used for access site triage.
• The choice between RRA versus LRA access is based on operator preference. • Ulnar artery access is an alternative among experienced operators for patients with prohibitive RA anatomy but may be associated with a higher rate of discomfort or hematoma formation.
• Ultrasound guidance facilitates vascular access, particularly in the setting of a weak pulse, hypotension, cardiogenic shock, or transulnar access.
• Low-profile hydrophilic sheaths should be used to reduce patient discomfort and to prevent RA spasm.
Pharmacology
Although the pharmacological management of patients with TRA in ACS is similar to that in patients without ACS undergoing diagnostic coronary angiography or PCI, pain management may be even more important in this setting given the higher rate of active chest discomfort at rest during PCI for ACS.
Analgesia
Alleviating discomfort and anxiety is an important factor that helps prevent stimulation of central neural pathways and arterial vasoconstriction. 115, 116 Administration of a low dose of a combination of fentanyl and midazolam has been shown to reduce patient discomfort, the incidence of RA spasm (2.6% versus 8.3%; P<0.001), and access site crossover (9.9% versus 15.0%; P=0.001) compared with control. 117 Administration of topical lidocaine may further reduce pain associated with arterial puncture and sheath insertion, but intra-arterial use of lidocaine is not effective.
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Antispasmolytic RA spasm can be minimized with the use of intra-arterial vasodilators. Spasmolytic agents should be used after sheath insertion and may also be used with each catheter exchange or before sheath removal. [119] [120] [121] The optimal agent or combination of agents is not defined, but most investigations have focused on calcium channel blockers or nitroglycerin. Although verapamil has been the most widely used calcium channel blocker, the benzothiazepine and dihydropyridine derivatives have been reported to be effective in reducing spasm, with little evidence to date to suggest intraclass differences in similarly potent doses. 122 Various nitrate formulations can also be effective in preventing radial spasm. 123, 124 Typically, an intra-arterial nitroglycerin dose of 100 to 200 µg is used. Because of the short pharmacological half-life of nitroglycerin, however, many investigations have focused on coadministration with calcium channel blockers. A recent meta-analysis concluded that verapamil 5 mg, with or without nitroglycerin, was the most effective and frequently used spasmolytic agent. 122 Vasodilators, however, may need to be avoided or used in smaller doses in patients presenting with hypotension, inferior myocardial infarction with suspected right ventricular involvement, severely reduced left ventricular ejection fraction, or severe aortic stenosis. Nonpharmacological interventions, such as induction of reactive hyperemia and forearm heating, may also reduce RA spasm by promoting arterial vasodilation. 125, 126 Adjunctive Anticoagulation Procedural anticoagulation, in combination with other procedural best practices such as maintenance of patent hemostasis (MOPH), is critical to preventing RAO. The rate of RAO is inversely correlated to activated clotting time. The optimal dose of unfractionated heparin is 50 U/kg (up to 5000 U) for diagnostic catheterization, 27, 28, 127, 128 and intravenous administration and intraarterial administration have similar efficacy. 129 Alternative anticoagulants at comparative doses, such as bivalirudin or enoxaparin, have an efficacy similar to that of unfractionated heparin in the prevention of RAO. [130] [131] [132] The adequacy of warfarin or direct oral anticoagulants, alone or in combination with heparin, for procedural anticoagulation and prevention of RAO is less certain. Two observational studies demonstrated conflicting results about the benefit of heparin (50 U/kg) in patients undergoing TRA catheterization with therapeutic international normalized ratio levels, but neither demonstrated evidence of increased bleeding. 33, 132 The use of heparin in patients on warfarin therapy undergoing TRA catheterization does not appear to have an adverse impact on time to arterial hemostasis. 133 Thus, use of adjunctive heparin in patients with therapeutic oral anticoagulant levels appears reasonable as a means of preventing RAO, but further investigation is warranted.
Summary of Recommendations
• Administration of local anesthesia, achievement of mild to moderate sedation, and provision of a warm environment are interventions that reduce patient anxiety, discomfort, and RA spasm.
• Calcium channel blockers (verapamil 2.5-5 mg, diltiazem 2.5-5 mg, or nicardipine 250-500 µg) and nitroglycerin (100-200 µg) reduce RA spasm and should be administered intra-arterially after sheath insertion and possibly with catheter exchanges or before sheath removal.
• Caution should be exercised with the use of spasmolytics in patients with cardiogenic shock, severely reduced ejection fraction, or severe aortic stenosis.
• Intraprocedural anticoagulation (unfractionated heparin 50 U/kg up to 5000 U or comparable doses of enoxaparin or bivalirudin) should be administered to all patients (including those on therapeutic oral anticoagulation) to prevent RAO and should otherwise follow current guidelines in ACS management.
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TRA Wire and Catheter Selection
Navigation of RA, Brachial Artery, and AortoSubclavian Artery Tortuosity Variations in RA and aorto-subclavian anatomy may pose a challenge to wire navigation and catheter manipulation during TRA angiography and PCI and increase procedural time. 134, 135 Navigating these variations in a timely manner is of the essence, particularly in the timesensitive STEMI setting. Use of a 1.5-mm-radius J-tip 0.035-in wire has multiple advantages over angle-tip hydrophilic 0.035-in wires, including minimized vessel wall contact and associated trauma and spasm, preferential following of the path of larger vessels, and avoidance of smaller branches. This allows navigation in the majority of cases without fluoroscopy. If a standard or 1.5-mm-radius J-tip wire does not traverse the upper extremity vasculature easily, a 0.014-in coronary wire may be used under fluoroscopic guidance with a subsequent exchange for a 0.035-in J wire. RA loops may straighten with wire exchange or by gently pulling back the catheter with counterclockwise torque. Attempts to straighten a 360° loop, however, may be futile and often are associated with patient discomfort and greater radiation exposure and contrast volume.
Significant subclavian tortuosity can often be negotiated with the aid of deep inspiration that straightens the angle between the innominate artery and the ascending aorta. If the wire and catheter advance to the descending aorta, positioning the catheter at the aortic knob in a left anterior oblique image and applying a counterclockwise rotation of the catheter during deep inspiration will facilitate advancement into the ascending aorta. 136 Once the catheter is safely seated in the ascending aorta, all subsequent catheter exchanges should be performed with an exchangelength wire. If tortuosity is significant, a stiff-bodied exchange-length wire or a long (70 cm) hydrophilic sheath may be used.
Occasionally, guide catheters may meet resistance when the leading edge catches tortuous arterial segments. This obstacle can be overcome with either the balloon-assisted tracking or the catheter-assisted tracking technique. 137, 138 The principle of both techniques involves telescoping a smaller-caliber device through the guide to smooth the transition between the wire and guide catheter. With balloon-assisted tracking, an inflated coronary balloon (ie, 2.0×15 mm for 6F guides) is positioned with several millimeters of the inflated balloon protruding outside the guide catheter tip. The unit is advanced together over a 0.014-in wire until the point of obstruction is passed. 137 Alternatively, if a 0.035-in wire is being used, an undersized 125-cm multipurpose, Judkins right 4.0, or pigtail catheter can be telescoped through the guide and advanced in similar fashion.
Catheter Selection
Although a multiple-catheter strategy using Judkinsshaped catheters is preferred among the majority of operators (Judkins right 4.0 for the right coronary artery, Judkins left 3.5 for the left coronary artery if RRA, Judkins left 4.0 for the left coronary artery if LRA), 139, 140 dedicated TRA catheters (eg, Kimny, Tiger, Jacky, DxTerity, Ultimate) allow a single catheter to be used to engage either coronary ostium. [141] [142] [143] It is uncertain, however, if, with experience, a single-catheter strategy to diagnostic coronary angiography is a timesaving measure in the setting of ACS. 141, 144, 145 The majority of PCIs (including treatment of complex bifurcations and use of covered stents and aspiration devices) can be performed via 6F guide catheters. Larger guide catheters are required for the use of an aspiration device with two 0.014-in wires in the coronary artery, use of a rotational atherectomy burrs >1.75 mm, or simultaneous deployment of 2 stents. For larger guide catheters, sheathless guide techniques or a thinwalled 7-in-6F sheath may be used. [146] [147] [148] As with any PCI, guide catheter selection should take into account the feasibility of engaging the coronary artery balanced with adequate support to complete the procedure, and appropriate guide catheter selection is another potential time-saving measure in the ACS setting. Inadequate support accounts for 7% to 17% of TRA PCI failures, 77, 100 but this is less relevant as operator experience increases. 100 For the left coronary artery, most operators prefer the extra backup single-curve guide catheters they usually use with TFA (eg, EBU, XB, Voda). 139 These catheters offer passive backup support from the contralateral sinus of Valsalva and provide deep-seating capability. Alternatively, Amplatz left (1 or 2) catheters also can provide excellent passive backup support and may be preferred for more complex interventions. For the right coronary artery, the most common choice is the Judkins right catheter. 139 However, the Judkins right catheter may not provide sufficient support. For increased backup support and for patients with a dilated aortic root or a right coronary artery with an anterior or "shepherd's crook" origin, preferred guide catheter shapes include Amplatz left (0.75 or 1), MAC (3.0 or 4.0), XB-RCA, and Ikari left (3.5 or 4.0) guides. 149 The choice of guide catheters for primary PCI in STE-MI is similar to that of elective PCI. However, because of the time-sensitive nature of primary PCI, consideration may be given to becoming familiar with the singleguide catheter technique with an extra backup (3.5 or 3.75) or dedicated TRA guide catheters (Ikari left, MAC, Kimny). These guides can engage either the right or left coronary artery and provide the option of passive or active support, depending on the technique of engagement. 141, 144, 145, 150 Ultimately, though, operators should choose the guide catheter strategy that they find most comfortable.
Special Patient Populations
In general, LRA is preferred in patients with prior CABG because it allows cannulation of the left internal mammary artery, usually with an internal mammary artery or VB-1 catheter, and a more familiar approach to grafts originating from the ascending aorta. 139 In the case of bilateral mammary grafts, the left subclavian artery can be cannulated from right-sided TRA, but TFA may be a more suitable option. For grafts originating from the ascending aorta, catheters with a longer curve (eg, multipurpose, Amplatz) may be needed to engage left-sided grafts. 151, 152 Catheter extensions (eg, Guideliner, Guidezilla) can improve backup support and facilitate deep intubation during bypass graft interventions if needed. 152, 153 Recent data suggest that TRA in cardiogenic shock is both safe and feasible and may be associated with reduced mortality. In the United Kingdom, for example, the use of TRA in cardiogenic shock increased from 9.5% in 2006 to 34.2% in 2012 (P for trend <0.0001), and its use was associated with a significant reduction in 30-day mortality (HR, 0.54; 95% CI, 0.50-0.60). 154 A meta-analysis of 8 studies and 8131 patients showed similar findings with a significant reduction in all-cause 30-day mortality associated with TRA compared with TFA (adjusted relative risk, 0.55; 95% CI, 0.46-0.65). 155 The benefits of TRA in cardiogenic shock include decreased risk of bleeding and vascular complications and sparing of the femoral arteries for insertion of hemodynamic support devices.
Summary of Recommendations
• A 1.5-mm-radius J-tip 0.035-in wire may safely navigate the majority of peripheral tortuosity.
• Deep inspiration and use of stiff-bodied J wires for catheter exchanges may facilitate procedures in the presence of significant aorto-subclavian tortuosity.
• For difficult upper extremity anatomy, use of a 0.014-in wire with subsequent exchange to a 0.035-in wire may be considered.
• Balloon-assisted tracking and catheter-assisted tracking techniques may also help navigate catheters traversing significant upper extremity vascular tortuosity or spasm.
• Operator TRA experience and preference largely dictate diagnostic and guide catheter selection.
• TRA in cardiogenic shock is both safe and feasible and may be associated with reduced mortality.
TRA Site Management
Prevention and Management of RAO
The most common complication of TRA is RAO. Given the presence of dual circulation and extensive collateralization through the interosseous arteries to the hand, RAO after TRA is often not clinically apparent. However, best procedural practice requires techniques that allow for RA patency to protect future vascular access. A previously published TRA consensus statement recommends MOPH during sheath removal and full intraprocedural anticoagulation given that these measures have consistently been shown to reduce RAO after TRA. 27, 156 More recent data demonstrate that the addition of prophylactic simultaneous ipsilateral ulnar artery compression reduces RAO. In an RCT of 3000 patients undergoing diagnostic angiography with 5F sheaths, ulnar compression reduced 30-day RAO from 3.0% to 0.9% compared with MOPH alone (P=0.0001) without evidence of hand ischemia. 157 In another RCT of 240 patients undergoing diagnostic or interventional procedures with 6F sheaths, ipsilateral ulnar compression reduced RAO from 5% to 0% compared with MOPH alone (P=0.01). 158 When RAO is identified early after compression and hemostasis, ≈50% will recanalize later within 1 to 3 months. Some data suggest that ipsilateral ulnar compression for 1 hour may improve restoration of radial patency. 159 Administration of systemic anticoagulation (eg, low-molecular-weight heparin) for 1 month may also promote recanalization. 160 
Management of TRA Site Complications
The incidence of major vascular complications after TRA is low. Reported complications include hematoma, perforation, RA spasm, pseudoaneurysm, arteriovenous fistula, compartment syndrome, hand ischemia, persistent postprocedural pain, neurological deficits, infection, and aseptic granuloma. 161, 162 TRA site hematomas are generally small and readily managed with manual compression, adjustment of compression band pressure, or repositioning of the compression band to a more proximal location. Hematoma formation proximal to the access site (eg, forearm, upper arm) may indicate arterial perforation, usually of a side branch. Intraprocedural recognition does not, however, prohibit continuation of the procedure because the intraluminal sheath or catheter can tamponade the perforated segment and resolve the problem. 163 In these cases, forearm angiography at the conclusion of the case is strongly advised. In cases of severe bleeding during or after the procedure, extrinsic compression with an elastic bandage or blood pressure cuff inflated to subocclusive pressure can achieve hemostasis. 161, 163 In rare occasions when recognized very late or when hemostasis cannot be achieved with the above measures because of an arterial laceration, surgical repair of the laceration and evacuation of hematoma may be required to avoid compartment syndrome.
RA spasm that is refractory to conventional interventions (intra-arterial vasodilator therapy, sedation and analgesia, forearm warming, and reactive hyperemia) may require general anesthesia or regional nerve block. Pseudoaneurysm can usually be managed with manual compression alone. 161, 164 Thrombin injection is not recommended because a short neck may disseminate a thrombus to the hand. An arteriovenous fistula is most often managed conservatively. Indications for surgical repair include symptomatic arterial steal phenomenon, venous congestion of the extremity, or high-cardiacoutput state.
161,165
Summary of Recommendations
• In addition to previously recommended MOPH and full procedural anticoagulation, simultaneous prophylactic ulnar artery compression may be considered to prevent RAO.
• Simultaneous ulnar artery compression and systemic anticoagulation may also be used to treat RAO.
• Major vascular complications after TRA are uncommon, and their consequences are generally benign when recognized early and managed appropriately.
Nursing Considerations
Preprocedural Care and Patient Comfort
In the setting of ACS, it is important that nurses who first respond to the patient are aware of the institution's approach to TRA. Identification bands and peripheral intravenous access should not be placed near the potential puncture site; repositioning these items in the cardiac catheterization laboratory may cause unnecessary delay in door-to-reperfusion time.
Interventions to reduce RA spasm are important to procedural success and include maintenance of a comfortable temperature and quiet environment during the procedure. Although patient comfort is not always optimal on catheterization laboratory tables, the TRA technique also affords increased flexibility with patient positioning. For example, elevation of the torso with the use of a wedge and patient leg movement (knee flexion and hip rotation) are better tolerated with TRA than TFA. This may be of particular benefit in the ACS setting, especially in patients with pulmonary edema or sufficient ongoing chest pain that precludes them from lying flat or still.
Postprocedural Care
As described above, MOPH is of key importance. 156 Acute symptomatic RAO is extremely rare, but the presence of hand or finger pain, weakness, discoloration, reduced temperature, or sensory deficit should prompt immediate evaluation. Although numbness and tingling are often benign, these symptoms deserve prompt attention.
There is no clear consensus on the optimal hemostatic pressure weaning protocol. In the CRASOC I, II, and III studies (Compression of Radial Arteries Without Occlusion), shorter compression times resulted in correspondingly lower rates of RAO: 9.4% with 4 hours of compression, 4.8% with 3 hours, 3.0% with 2 hours, and 2.3% with 1.5 hours. Bleeding and recompression rates increased with shorter compression times, however: 1.2% at 4 hours, 3.7% at 3 hours, 5.5% at 2 hours, and 8.4% at 1.5 hours. 166 Most physicians recommend RA compression for at least 60 minutes after a diagnostic procedure and for 120 to 180 minutes after PCI. Slightly longer compression times may be considered for patients with uninterrupted oral or intravenous anticoagulation. Assessment for forearm or wrist hematoma is important. Compartment syndrome can occur if the hematoma is not promptly recognized and identified or appropriately controlled. In rare cases, venous pooling may also cause pain and contribute to compartment syndrome.
Patients who undergo a TRA procedure do not require bed rest for access site management, and time to ambulation is dictated primarily by the effects of procedural sedation. Postprocedural care pathways and protocols should take the benefits associated with early ambulation into account to optimize patient comfort and satisfaction and to maximally affect healthcare systems resource use.
After compression device removal, the TRA site heals rapidly, and a return to activities of daily living should be expected the following day. Aggressive use of the wrist (eg, golf, tennis, construction work, driving) might be delayed for several days in certain circumstances.
Integration Into a Catheterization Laboratory System
Care of patients during and after TRA procedures differs from the care of patients who undergo TFA procedures. Staff education about TRA, how it differs from TFA, and its relative benefits is critical for staff engagement and adoption of appropriate practices and protocols. Selection of TRA "champions" is a recommended tool in this process.
Summary of Recommendations
• Nursing goals should include optimization of patient comfort. This may reduce RA spasm and increase the chances of procedural success.
• Distal pulse, plethysmography signal, forearm pain and tenderness, and skin temperature and color should be monitored during the postprocedural observation period.
• The presence of forearm pain should raise suspicion of hematoma. Early recognition of hematomas and venous congestion is critical to avoid more significant complications.
• Bed rest should be avoided, and early ambulation needs to be encouraged.
UNCERTAINTIES AND FUTURE DIRECTIONS Mechanism for and Magnitude of Mortality Benefit
Possible mechanisms to explain the morality benefit observed with TRA in STEMI focus largely on bleeding events and, more specifically, hemorrhagic access site complications. Several explanations for why TRA in STEMI reduces mortality are as follows: (1) Patients with STEMI are at higher risk for bleeding and have independently increased rates of mortality compared with other patients with ACS 167 ; (2) the rate of PCI with its associated use of adjunctive antithrombotic therapy is higher in STEMI; (3) STEMI care often involves the use of more potent antiplatelet and antithrombotic therapies 168 ; (4) the underlying plaque physiology in STEMI may increase the risk of ischemic complications if antiplatelet therapy is discontinued in the setting of bleeding 169 ; and (5) the urgency of STEMI-related procedures might result in deviation from best practices for TFA and increase the risk and consequences of TFA-related bleeding complications. Other potential explanations for the observed TRA-associated mortality benefit in patients with STEMI include the observed associated lower rates of acute kidney injury with TRA versus TFA 87, 87, 90, 170 and the fact that earlier ambulation and shorter length of stay might confer protection against venous thromboembolism, hospital-related infections, and iatrogenic complications. 4, 43, 50 Potential for Further Improvements in Healthcare Costs With a Dedicated TRA Strategy
The spectrum and complexity of disease among patients with ACS vary, but it is becoming clear that shorter durations of care are beneficial for select populations. In the setting of elective PCI, same-day discharge has been shown to be safe, cost-effective, and preferred by patients. [171] [172] [173] [174] [175] A recent singlecenter, retrospective analysis of 2273 patients who underwent PCI for ACS (84% with unstable angina) between 2011 and 2014 evaluated rates of hospital readmission, bleeding, and all-cause mortality at 30 days. 175 Thirty-day outcomes revealed that 23% of the patients selected for same-day discharge had lower readmission rates than those determined by their physician to go home the following day (7.3% versus 10.9%; P=0.03), and rates of mortality and bleeding at 30 days were similar between the same-day and next-day discharge groups. It is possible that select low-risk patients with ACS may be suitable for accelerated discharge pathways. RCTs to establish specific criteria, including clinical factors and risk scores, that may identify patients with ACS acceptable for early hospital discharge are warranted.
CONCLUSIONS
TRA should be considered the default strategy in the invasive management of patients with ACS. In the ACS population, TRA is associated with a significantly lower incidence of bleeding and vascular complications and potentially mortality compared with TFA. The mortality benefit is clearly observed in high-risk ACS (eg, STEMI, cardiogenic shock) and in patients with high predicted bleeding risk. The use of TRA in these patients requires operator and institutional experience to optimize procedural outcomes. Compared with TFA, TRA is also associated with improved quality of life, reduced healthcare resource use, and reduced healthcare costs. For these reasons and to facilitate adequate procedural expertise for high-risk patient subgroups, TRA should be considered the preferred access site strategy.
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